<DOC>
	<DOCNO>NCT01206088</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety nilotinib patient Imatinib resistant intolerant CML-CP AC . Efficacy evaluation make Complete cytogenetic response rate ( CCyR ) 12 month nilotinib administration .</brief_summary>
	<brief_title>Tasigna Glivec-resistant Intolerant Patients CML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Imatinib resistant chronic myelogenous leukemia chronic phase cytogenetic confirmation Philadelphia chromosome . Documented chronic phase CML define : &lt; 15 % blast peripheral blood bone marrow &lt; 30 % blast plus promyelocytes peripheral blood bone marrow &lt; 20 % basophils peripheral blood ≥ 100 x 109/L ( ≥ 100,000 /mm3 ) platelets No evidence extramedullary leukemic involvement , exception hepatosplenomegaly patient CHR ( complete hematologic response ) 3 month treatment , mimical cytogenetic response ( Ph+ &lt; 65 % ) 6 month treatment , major cytogenetic response ( Ph+ &lt; 35 % ) 12 month treatment . Or Imatinib resistant Philadelphia positive CMLAC define lease one follow bast crisis treatment . &lt; 30 % ≥ 15 % blast peripheral blood bone marrow ≥ 30 % blast plus promyelocytes peripheral blood bone marrow ≥ 20 % basophils peripheral blood &lt; 100 x 109/L ( ≥ 100,000 /mm3 ) platelet without related treatment progression CMLAP Imatinib treatment , hematologic response bone marrow least 4 week treatment imatinib . Progression AP define increase number 50 % peripheral WBCs , blast , basophil platelet . definition Imatinib intolerance CMLCP AP patient discontinue imatinib treatment dosage due Grade 3 4 nonhematologic adverse event Grade 4 hematologic adverse event sustain 7 day even best complementary therapy . WHO performance scale ≤ 2 provide sign informed consent form Cardiac dysfunction : LVEF &lt; 45 % echocardiography , use pacemaker , Congenital long QT syndrome know family history long QT syndrome , History presence clinically significant ventricular atrial tachyarrhythmias , Clinically significant rest brachycardia ( &lt; 50 beat per minute ) , QTc &gt; 450 msec baseline ECG ( use QTcF formula ) , Myocardial infarction within 12 month prior start study , Other clinically significant heart disease ( e.g . unstable angina , congestive heart failure uncontrolled hypertension ) . Known cytopathologically confirm CNS infiltration ( absence suspicion CNS involvement , lumbar puncture require ) . Severe uncontrolled medical condition ( i.e . uncontrolled diabetes , active uncontrolled infection ) . History significant congenital acquire bleed disorder unrelated cancer . Treatment CSGF within 1 week Day 1 except Erythropoietin . History noncompliance medical regimen inability grant consent . Use therapeutic coumarin derivative ( i.e. , warfarin , acenocoumarol , phenprocoumon ) Patients another primary malignancy except primary malignancy neither currently clinically significant require active intervention Patients actively receive therapy strong CYP3A4 inhibitor ( e.g , erythromycin , ketoconazole , itraconazole , voriconazole , clarithromycin , telithromycin , ritonavir , mibefradil ) treatment either discontinue switched different medication prior start study drug . See link complete list medication : http : //medicine.iupui.edu/flockhart/table.htm.. Novartis must contact patient need start drug study treatment . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection , gastric bypass surgery ) History acute pancreatitis within 1 year study entry past medical history chronic pancreatitis . patient diagnose HIV infection . patient hypersensitivity nilotinib additives Patients currently receive treatment medication potential prolong QT interval treatment either discontinue switched different medication prior start study drug ( Please see http : //www.torsades.org/medicalpros/druglists/printabledruglist.cfm comprehensive list agent prolong QT interval ) Patients : ( ) pregnant , ( b ) breast feeding , ( c ) childbearing potential without negative pregnancy test prior baseline ( ) male female childbearing potential unwilling use contraceptive precaution throughout trial Patients rare genetic disease galactose intolerance , moderate lactase deficiency glucosegalactose absorption disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>